The article documents and analyzes patients organizations- and groups of activists’ “evidence-based activismâ€, and the compound dynamic interplay between politics of illness and politics of knowledge it entails in the four condition areas studied: ADHD, Alzheimer, rare diseases...

Analyses the role of European patients’ organizations in the process of Europeanization of healthcare policies by exploring the types of organizations constituted by European patients’ organizations and the form of activism they develop.

"The widespread condemnation of drastic price increases on life-saving drugs highlights our growing dependency on and vulnerability to international pharmaceutical conglomerates. However, aren't the interests of the public supposed to supersede the pursuit of private profit? In his new work,...

Cambodia is expected to graduate from Least Developed Country status soon, at which time it will be required to make patents available for pharmaceutical products and processes to meet its obligations under the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS). Given its...

The United States government is running a campaign to characterize other industrialized countries as free riding on high U.S. pharmaceutical prices and innovation in new drugs. The campaign is based on the argument that lower prices imposed by price controls in these countries do not pay for...

This paper presents a historical perspective on the evolution of relationships between the pharmaceutical industry and physicians in two countries, the United States and Finland. Despite divergence early the twentieth century, and the absence of any large pharmaceutical firms based in Finland,...

Canada has strengthened intellectual property (IP) protections for pharmaceutical drugs several times over the last three decades. These changes were intended to lengthen the period of market exclusivity for new brand drugs and thereby allow them to earn additional sales revenues that could be...